Table 3.
Uni- and Multivariate Analysis for the Prediction of CSS
| Univariate Analysis |
Multivariate Analysis |
|||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P | HR | 95%CI | P | |
| Cancer-specific survival | ||||||
| Age (≤75 y vs. >75 y) | 2.50 | 1.30-4.57 | 0.007 | 1.96 | 0.97-3.80 | 0.058 |
| Sex (male vs. female) | 1.19 | 0.59-2.22 | 0.591 | |||
| T-Stage (pT2 vs. p3-4) | 1.76 | 0.91-3.73 | 0.009 | 1.73 | 0.84-3.84 | 0.136 |
| Grade (G2 vs. 3-4) | 1.22 | 0.62-2.69 | 0.574 | |||
| Nodal-status (N0 vs. N+) | 2.32 | 1.29-4.15 | 0.006 | 1.97 | 0.96-4.14 | 0.065 |
| LVI | 1.84 | 1.05-3.344 | 0.033 | 1.22 | 0.58-2.53 | 0.587 |
| Concomitant carcinoma in situ | 1.34 | 0.68-2.95 | 0.408 | |||
| Adjuvant chemotherapy | 0.79 | 0.36-1.97 | 0.587 | |||
| Micropapillary | 1.50 | 0.61-3.13 | 0.343 | |||
| Her2 | 2.11 | 1.19-3.82 | 0.009 | 2.11 | 1.11-4.21 | 0.024 |
| ESR | 2.81 | 1.38-9.32 | 0.023 | 1.25 | 0.43-4.53 | 0.697 |
| PGR | 0.63 | 0.35-1.10 | 0.110 | |||
| Ki67 | 1.80 | 0.93-3.82 | 0.079 | 1.59 | 0.79-3.51 | 0.197 |